CD19 and acute lymphoblastic leukemia: Our previous study showed that CD19/CD22 CAR-T therapy for r/r B-ALL followed by allo-HSCT significantly improved patient survival, with a 1-year OS of 87.7% and 1-year event-free survival (EFS) of 73% (8).